Shared on08 Aug 25Fair value Increased 13%
The upward revision in Beauty Health’s consensus price target to $1.75 is primarily driven by a substantial increase in revenue growth forecasts and a lower discount rate, signaling improved growth expectations and a more favorable risk profile. What's in the News Company updated earnings guidance, projecting Q3 net sales of $65–$70 million and full-year net sales of $285–$300 million, citing strong first half performance.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 9.04%
AnalystConsensusTarget has increased revenue growth from -1.7% to 2.7%, decreased profit margin from 5.6% to 5.0%, decreased future PE multiple from 18.8x to 15.5x and decreased shares outstanding growth rate from 0.0% to 0.0%.